Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to $5.5 million.

  • Immuneering's Cash from Investing Activities rose 75.26% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $26.4 million, marking a year-over-year increase of 262.30%. This contributed to the annual value of $26.4 million for FY2024, which is 262.30% up from last year.
  • Per Immuneering's latest filing, its Cash from Investing Activities stood at $5.5 million for Q4 2024, which was up 201.39% from -$5.4 million recorded in Q3 2024.
  • Over the past 5 years, Immuneering's Cash from Investing Activities peaked at $22.2 million during Q2 2022, and registered a low of -$52.8 million during Q3 2021.
  • Its 3-year average for Cash from Investing Activities is $6.3 million, with a median of $6.8 million in 2022.
  • Per our database at Business Quant, Immuneering's Cash from Investing Activities crashed by 941,746.24% in 2021 and then skyrocketed by 111,852.97% in 2022.
  • Quarterly analysis of 5 years shows Immuneering's Cash from Investing Activities stood at -$38,058 in 2020, then tumbled by 59,829.41% to -$22.8 million in 2021, then soared by 135.74% to $8.2 million in 2022, then tumbled by 61.57% to $3.1 million in 2023, then spiked by 75.26% to $5.5 million in 2024.
  • Its last three reported values are $5.5 million in Q4 2024, -$5.4 million for Q3 2024, and $5.0 million during Q2 2024.